Sandoz Canada News

portlet_teaser_sandoz_news.jpg

Sandoz Canada Launches First Non-Prescription Naloxone Approved by Health Canada for Treating Opioid Overdoses

Sandoz announces plans for five major global biosimilar launches by 2020

Sandoz Canada concludes a new collective agreement with unionized employees at its Boucherville plant

New data demonstrates sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products.

Sandoz Canada is committed to maintain a supply of injectable medicines during work stoppage by unionized employees at its Boucherville facility.

Sandoz broadens its pharmaceutical portfolio with EURO-PHARM's North American product line.To learn more on these products,

Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency

Sandoz Canada launches PrSandoz® Duloxetine, a generic version of Cymbalta*, for the treatment of depression and anxiety symptoms

Addition of a new product to the Sandoz portfolio in Canada: PrVistitan TM (bimatoprost ophthalmic solution 0.03% w/v) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

  • 16-05-2016

New research highlights need for a competitive functioning biologics market to achieve full potential of biosimilars.

Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI* indicated for pulmonary infections in cystic fibrosis patients.

Corporate Responsibility. Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. This report shows the variety of approaches and models used to expand access to healthcare globally.

Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer’s biosimilar infliximab in EEA

Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Sandoz Canada expands its cancer medication portfolio with the launch of PrOxaliplatin Injection.

Welcome to Sandoz Canada

Health is our most precious asset. That’s why, at Sandoz Canada, we respond to our customers’ needs by acting quickly to offer an unparalleled range of high-quality, affordable generic products. But that’s not all. Our vision goes beyond the production of standard generic products. We lead by example. We develop and market a wide range of differentiated products that make a real difference. We help cure patients and save lives. Because our priority is people, whether they are our patients, our pharmacists, our business partners or our employees.

Sandoz Careers

sandoz_careers.jpg

Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

New Products

Sandoz broadens its pharmaceutical portfolio with EURO-PHARM's North American product line.

To learn more on these products,

click here.

 

S.O.S. NaloxoneTM Hydrochloride Injection

New OTC Naloxone Hydrochloride Injection available for sale in Canada without a prescription.

Click here to see a demonstration video explaining the administration of naloxone.

Click here for the Consumer Information Leaflet

     

Sandoz  History

   

Take a virtual journey into the historical roots of our company.

Explore our history >

 

EN_PNG_LOGO_HPSA.PNG

 Don’t throw them out, visit www.healthsteward.ca

Slideshow Background Images